In a report released today, Kevin DeGeeter from Oppenheimer assigned a Hold rating to Vericel (VCEL). The company’s shares closed last Wednesday at $56.52, close to its 52-week high of $64.90.
According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 45.0% and a 49.7% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Cyclacel Pharmaceuticals, Rocket Pharmaceuticals, and Sensei Biotherapeutics.
Currently, the analyst consensus on Vericel is a Moderate Buy with an average price target of $60.80.
See today’s analyst top recommended stocks >>
The company has a one-year high of $64.90 and a one-year low of $12.82. Currently, Vericel has an average volume of 907.1K.
Based on the recent corporate insider activity of 25 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VCEL in relation to earlier this year. Most recently, in March 2021, Alan Rubino, a Director at VCEL bought 5,000 shares for a total of $226,000.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
